Moffitt Researchers Discover New Therapeutic Target for Non-Small Cell
Disrupting Jagged2 signaling reprograms immune cells to fight tumors
Disrupting Jagged2 signaling reprograms immune cells to fight tumors
Drs Nassar and Bou Farhat explain how tumor-only NGS could address the limitations of IHC testing for MMR mutation signatures across several tumor types.
PHILADELPHIA (April 29, 2024) —Following her double mastectomy in October of 2019, Agnes Judge fell into a deep depression – experiencing what she recalls as…
Manmeet Singh Ahluwalia, MD, MBA, FASCO, discusses how advancements in precision medicine have improved outcomes for patients with brain metastases.
Dr. Bose discusses his perspective on quality-of-life preservation for his patients with myelofibrosis, including the symptoms that have the most negative impact on patients’ quality…
Hypofractionated IMRT with concurrent chemotherapy appears to be well tolerated as post-operative treatment in patients with cervical cancer.
In this issue of Blood, Leung et al1 present preclinical findings demonstrating the potential of neoantigen-specific T cells to recognize acute myeloid leu
Using a cohort from the Pathways Study, researchers sought to determine the influence of healthy eating habits on risk of heart disease among women treated…
The FDA has granted breakthrough therapy designation to ziftomenib for the treatment of NPM1-mutant acute myeloid leukemia.
Journal of Neuro-Oncology – Diffuse midline gliomas (DMG) include all midline gliomas with a point mutation to the histone H3 gene resulting in the substitution…
The 15 inductees have been selected by their peers for their remarkable achievements in oncology research and clinical practice.